Evidence-Based Ways to Improve Your DEXA Bone Density Score

What Your DEXA T-Score Actually Measures

A DEXA (dual-energy X-ray absorptiometry) scan quantifies bone mineral density (BMD) in grams per square centimeter at the lumbar spine, femoral neck, and total hip. The result is reported as a T-score, which compares your BMD to that of a healthy 30-year-old reference population. The World Health Organization defines three categories: normal (T-score ≥ -1.0), osteopenia (T-score between -1.0 and -2.5), and osteoporosis (T-score ≤ -2.5) [1].

Z-scores, by contrast, compare your BMD to age-matched and sex-matched peers. A Z-score below -2.0 in premenopausal women or men under 50 should prompt investigation for secondary causes such as hypogonadism, hyperthyroidism, celiac disease, or glucocorticoid use [2]. The ISCD's 2019 Official Positions recommend using Z-scores rather than T-scores for premenopausal women and men younger than 50 [2].

Your T-score is not fixed. Bone is living tissue undergoing constant remodeling, with osteoclasts resorbing old bone and osteoblasts forming new matrix. Every strategy below targets this remodeling balance.

Resistance and Impact Exercise

Weight-bearing and resistance exercise produce the most consistent non-pharmacological BMD improvements. Load the skeleton, and it responds.

A 2022 meta-analysis of 59 RCTs (N=5,652) published in Bone found that combined resistance and impact training increased lumbar spine BMD by 1.37% and femoral neck BMD by 0.87% over 12 months compared to controls [3]. High-impact activities (jumping, stair climbing, jogging) generate ground-reaction forces exceeding 2 to 4 times body weight, which is the stimulus threshold for osteogenic adaptation according to Frost's mechanostat theory [4].

The LIFTMOR trial (N=101 postmenopausal women with low bone mass) tested high-intensity resistance and impact training (deadlifts, overhead press, back squats at 80% to 85% 1RM, plus jumping chin-ups) against a low-intensity home program. At 8 months, the high-intensity group gained 2.9% at the lumbar spine and 0.3% at the femoral neck, while the control group lost bone at both sites [5]. The protocol was safe. Zero fractures occurred [5].

Practical targets backed by the ACSM's position stand [6]:

• 2 to 3 sessions per week of progressive resistance training at 70% to 85% 1RM
• 50 to 100 jumps or impacts per session (box jumps, jump squats, skipping)
• Prioritize multi-joint movements that load the spine and hip (squat, deadlift, row)

Swimming and cycling, while excellent for cardiovascular health, do not provide meaningful osteogenic stimulus and should not be counted toward bone-loading goals.

Calcium and Vitamin D: Getting the Dose Right

Calcium and vitamin D form the nutritional foundation. Without adequate substrate, no pharmacological or exercise intervention reaches its full potential.

The Endocrine Society's 2024 clinical practice guideline recommends 1 to 000 mg of daily calcium for men aged 19 to 70 and premenopausal women, increasing to 1 to 200 mg for postmenopausal women and men over 70 [7]. Dietary sources (dairy, fortified foods, leafy greens) are preferred. Supplement only the gap between dietary intake and the target.

For vitamin D, the same guideline recommends 600 to 800 IU daily for most adults, with higher doses (1,000 to 2 to 000 IU) for individuals at risk of deficiency, targeting a serum 25(OH)D level of at least 30 ng/mL [7]. The VITAL trial (N=25,871) found that 2 to 000 IU/day of vitamin D3 without calcium co-supplementation did not reduce fracture incidence in a vitamin D-replete population [8]. This reinforces that vitamin D supplementation benefits those who are actually deficient, not everyone.

Calcium doses above 500 mg should be split. Fractional absorption drops sharply above that threshold. Calcium citrate does not require stomach acid and is preferred for patients on proton pump inhibitors.

Pharmacotherapy: When Lifestyle Is Not Enough

The AACE/ACE 2020 Clinical Practice Guidelines recommend pharmacotherapy for postmenopausal women and men over 50 with a T-score ≤ -2.5, a hip or vertebral fracture, or a FRAX 10-year probability ≥ 3% for hip fracture or ≥ 20% for major osteoporotic fracture [9].

Bisphosphonates (First-Line)

Alendronate (70 mg weekly), risedronate (35 mg weekly or 150 mg monthly), and zoledronic acid (5 mg IV annually) inhibit osteoclast-mediated resorption. The Fracture Intervention Trial (FIT, N=2,027) showed alendronate increased lumbar spine BMD by 8.8% and reduced vertebral fractures by 47% over 3 years [10]. Zoledronic acid in the HORIZON Key Fracture Trial (N=7,765) reduced hip fractures by 41% and vertebral fractures by 70% over 3 years [11].

Bisphosphonate holidays (temporary discontinuation after 3 to 5 years of oral or 3 years of IV therapy) are recommended by the ASBMR 2023 task force to minimize rare adverse events such as atypical femoral fractures and osteonecrosis of the jaw [12]. The residual effect of bisphosphonates, because they bind to bone matrix, provides continued protection during the holiday period.

Denosumab (RANKL Inhibitor)

Denosumab (60 mg subcutaneous every 6 months) blocks RANKL, preventing osteoclast formation. The FREEDOM trial (N=7,868) demonstrated an 8.8% lumbar spine BMD increase and 68% reduction in vertebral fractures over 3 years [13]. The 10-year extension data showed continuous BMD gains reaching 21.7% at the lumbar spine [14].

A critical caveat: discontinuing denosumab triggers rapid bone loss (the "rebound effect") and may increase vertebral fracture risk. The ASBMR and European Calcified Tissue Society recommend transitioning to a bisphosphonate before or immediately after stopping denosumab [15]. Never stop denosumab without a bridging plan.

Anabolic Agents (Bone Builders)

Teriparatide (20 mcg daily subcutaneous) and abaloparatide (80 mcg daily subcutaneous) are parathyroid hormone analogs that stimulate osteoblast activity. The Neer et al. key trial (N=1,637) showed teriparatide increased lumbar spine BMD by 9.7% and reduced vertebral fractures by 65% over 19 months [16].

Romosozumab (210 mg monthly subcutaneous for 12 months) inhibits sclerostin, simultaneously boosting bone formation and reducing resorption. The FRAME trial (N=7,180) showed a 13.3% gain in lumbar spine BMD at 12 months, the largest gain of any single osteoporosis agent [17]. The ARCH trial demonstrated that romosozumab followed by alendronate reduced fracture risk by 48% compared to alendronate alone [18]. Romosozumab carries a cardiovascular safety signal (the FDA label includes a boxed warning), so it should be avoided in patients with recent myocardial infarction or stroke within the prior year [18].

Sequencing Matters

The AACE 2020 guidelines recommend an "anabolic-first" strategy for very high-risk patients (T-score ≤ -3.0, recent fracture, or multiple fractures). Start with romosozumab or teriparatide for 12 to 24 months, then consolidate gains with a bisphosphonate or denosumab [9]. Starting with an antiresorptive and later switching to an anabolic agent produces smaller BMD gains than the reverse sequence, as demonstrated in the DATA-Switch study [19].

Hormonal Optimization

Estrogen deficiency is the primary driver of postmenopausal bone loss. Testosterone deficiency accelerates bone loss in men. Addressing these deficits is not optional if you want to move a T-score.

Estrogen and HRT

The Women's Health Initiative (WHI, N=16,608) showed that conjugated equine estrogen plus medroxyprogesterone acetate increased hip BMD by 3.7% and reduced hip fractures by 33% over 5.6 years [20]. The 2022 Endocrine Society guideline positions HRT as a first-line option for osteoporosis prevention in recently postmenopausal women (within 10 years of menopause or under age 60), particularly when vasomotor symptoms are also present [21].

Transdermal estradiol (0.025 to 0.05 mg/day patch) provides bone protection with a more favorable thrombotic risk profile than oral formulations. Even ultra-low-dose transdermal estradiol (0.014 mg/day) has demonstrated bone-protective effects at the spine in the ULTRA trial [22].

Testosterone Replacement in Hypogonadal Men

The Testosterone Trials (TTrials) Bone substudy (N=211, men ≥ 65 with T <275 ng/dL) found that 12 months of testosterone gel increased volumetric trabecular BMD at the lumbar spine by 7.5% compared to placebo, as measured by QCT [23]. The effect was concentration-dependent: men who achieved mid-normal testosterone levels (400 to 600 ng/dL) showed the largest gains.

Testosterone influences bone through both direct androgen receptor activation and aromatization to estradiol. In hypogonadal men with documented low BMD, TRT addresses a root cause rather than masking a symptom.

Lifestyle Factors That Erode Bone

Several modifiable habits directly suppress bone formation or accelerate resorption.

Smoking. A meta-analysis of 86 studies (N=40,753) published in Calcified Tissue International found that current smokers had 5.8% lower BMD at the lumbar spine and a 1.8-fold higher hip fracture risk compared to never-smokers [24]. Smoking impairs osteoblast function, reduces calcium absorption, and accelerates estrogen metabolism.

Alcohol. Consumption exceeding 2 drinks per day is associated with a dose-dependent increase in fracture risk. The FRAX model incorporates alcohol intake as an independent risk factor [25].

Glucocorticoids. Prednisone at ≥ 5 mg/day for 3 or more months causes the most common form of secondary osteoporosis. The American College of Rheumatology 2022 guideline recommends starting pharmacotherapy (bisphosphonate or denosumab) alongside glucocorticoids when the anticipated duration exceeds 3 months in adults over 40 [26]. Bone loss is fastest in the first 3 to 6 months of glucocorticoid therapy.

Protein. Protein intake below 0.8 g/kg/day is associated with lower BMD and higher fracture risk in older adults. A 2019 systematic review found that protein supplementation (especially with calcium and vitamin D co-supplementation) modestly improved hip BMD [27].

Monitoring Your Progress

Repeat DEXA scans should occur 1 to 2 years after initiating therapy. The ISCD 2019 positions state that the minimum interval for detecting real change (beyond machine precision error) is typically 1 year at the spine and 2 years at the hip [2]. Use the same machine and facility for serial scans to minimize interscan variability. The least significant change (LSC) for most clinical DEXA systems is approximately 3% to 5%, meaning a BMD change smaller than this may reflect measurement noise rather than true biological change.

Bone turnover markers (serum CTX for resorption, P1NP for formation) can confirm treatment response within 3 to 6 months, well before a repeat DEXA would show change. A CTX reduction of ≥ 25% from baseline suggests adequate antiresorptive effect [28]. The Endocrine Society notes that bone turnover markers are best used as adjuncts to, not replacements for, serial DEXA [28].

A T-score that remains stable on therapy is a successful outcome. Not every patient will show dramatic gains. Preventing further decline, particularly in the first 2 years of treatment, reduces fracture risk even without large numeric improvement.

The USPSTF recommends screening DEXA for all women aged 65 and older and for younger postmenopausal women with clinical risk factors [29]. For men, the Endocrine Society recommends screening at age 70 or earlier if risk factors (hypogonadism, glucocorticoid use, low body weight) are present [30]. HealthRX clinicians typically order baseline DEXA alongside hormonal panels to identify treatable contributors before they cause irreversible skeletal damage.